Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Part of paid clinical trials in Dothan, Alabama.
- Sponsor
- Alfasigma S.p.A.
- Study ID
- NCT02914535
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Filgotinib — DRUGTablet(s) administered orally once daily
- Placebo — DRUGTablet(s) administered orally once daily
Study Details
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
Key Dates
- First listed
- Sep 26, 2016
- Start date
- Feb 23, 2017
- Status verified
- May 2026
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 1,173 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Filgotinib 200 mg (blinded dosing)Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
- Experimental: Filgotinib 100 mg (blinded dosing)Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 336 weeks
- Placebo Comparator: Placebo (blinded dosing)Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks
- Experimental: Filgotinib 200 mg (open-label)Filgotinib 200 mg for up to 336 weeks
- Experimental: Filgotinib 100 mg (open-label)Filgotinib 100 mg for up to 336 weeks
Primary Outcome Measure
Overall Safety Profile of Filgotinib Evaluated by Proportion of Participants Experiencing Adverse Events and Abnormal Clinical Laboratory Tests [ Time Frame: Up to 336 weeks plus 30 days ]
Locations (57)
Find similar trials in Dothan, AL
Nationwide
By condition
Related Studies
- Immune Regulation in Ulcerative Colitis or Crohn s DiseaseRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Improving the Quality of Care for Adults With Inflammatory Bowel DiseaseEnrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
- The Influence of a Fasting Mimicking Diet on Ulcerative ColitisRecruiting · Stanford University · Palo Alto, California
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Sacramento, California